UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 14, 2015
Sanomedics, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
| 000-54167 |
| 27-3320809 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
444 Brickell Avenue, Suite 415, Miami, Florida |
| 33131 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant's telephone number, including area code (305) 433-7814
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 14, 2015, Keith Houlihan, the President and a member of the Board of Directors of Sanomedics, Inc. (the "Company"), resigned from all positions he held at the Company and its subsidiaries and from the Board of Directors, effective as of December 14, 2015.
In connection with the resignation of Mr. Houlihan, the Board of Directors has appointed David C. Langle as President and Chief Executive Officer, effective December 14, 2015. Mr. Langle has been the Company's Chief Financial Officer since 2013 and will continue in this role as well.
The biography of Mr. Langle is contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Sanomedics, Inc. |
| |
| Date: December 15, 2015 | By | /s/ David C. Langle |
|
|
| David C. Langle |
|
|
| Chief Executive Officer |
|
3